Basic Information
| LncRNA/CircRNA Name | CILA1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | tongue squamous cell carcinoma |
| ICD-0-3 | C02 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (CAL27, SCC9), TSCC tissues |
| Expression Pattern | up-regulated |
| Function Description | lncRNA 1 (CILA1) was discovered by using microarrays and was functionally identified as a regulator of chemo-sensitivity in TSCC cells. Upregulation of CILA1 promotes EMT, invasiveness, and chemo-resistance in TSCC cells, whereas the inhibition of CILA1 expression induces mesenchymal-epithelial transition (MET) and chemo-sensitivity, and inhibits the invasiveness of cisplatin-resistant cells both in vitro and in vivo. We also found that CILA1 exerts its functions via the activation of the Wnt/B-catenin signaling pathway. High CILA1 expression levels and low levels of phosphorylated B-catenin were closely associated with cisplatin resistance and advanced disease stage, and were predictors of poor prognosis in TSCC patients. These findings provided a new biomarker for the chemo-sensitivity of TSCC tumors and a therapeutic target for TSCC treatment. |
| Pubmed ID | 29699939 |
| Year | 2018 |
| Title | Chemotherapy-Induced Long Non-coding RNA 1 Promotes Metastasis and Chemo-Resistance of TSCC via the Wnt/B-Catenin Signaling Pathway. |
External Links
| Links for CILA1 | GenBank HGNC NONCODE |
| Links for tongue squamous cell carcinoma | OMIM COSMIC |